Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 70-74

  Schilder, Russell J ^a,i   Brady, William E ^b   Lankes, Heather A ^b   Fiorica, James V ^c   Shahin, Mark S ^d   Zhou, Xun C ^e   Mannel, Robert S ^f   Pathak, Harsh B ^g   Hu, Wei ^h   Alpaugh, R Katherine ^a   Sood, Anil K ^h   Godwin, Andrew K ^g  

^a FOX CHASE CANCER CENTER   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c SARASOTA MEMORIAL HOSPITAL   (United States)

^d ABINGTON MEMORIAL HOSPITAL   (United States)

^e NEW BRITAIN GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer; Dasatinib; Inhibition; Ovarian; SRC

Indexed keywords

BIOLOGICAL MARKER; CELL FREE DNA; DASATINIB; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; ASCITES; BLEEDING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; ENDOTHELIAL PRECURSOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INSOMNIA; MALAISE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIMARY PERITONEUM CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; STEM CELL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84865676963     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.009     Document Type: Article

References (34)

1. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 2011 183 203
2. M.C. Frame Src in cancer: deregulation and consequences for cell behaviour Biochim Biophys Acta 1602 2002 114 130
3. J.R. Wiener, C. Windham, B.C. Estrella, N.U. Parikh, P.F. Thall, and M.T. Deavers Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancer Gynecol Oncol 88 2003 73 79
4. T.J. Yeatman A renaissance for SRC Nat Rev Cancer 4 2004 470 480
5. Y. Pengetnze, M. Steed, K.F. Roby, P.F. Terranova, and C.C. Taylor Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line Biochem Biophys Res Commun 309 2003 377 383
6. T. Chen, Y. Pengetnze, and C.C. Taylor Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspace-9 independent activation of caspace-3 Mol Cancer Ther 4 2005 217 224
7. P. Ceppi, M. Papotti, V. Monica, M. Lo Iacono, S. Saviozzi, and M. Pautasso Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin Mol Cancer Ther 8 2009 3066 3074
8. J.R. Wiener, K. Nakano, R.P. Kruzelock, C.D. Bucana, R.C. Bast Jr., and G.E. Gallick Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model Clin Cancer Res 5 1999 2164 2170
9. L. Martin, and R. Schilder Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition J Clin Oncol 25 2007 2894 2901
10. L.Y. Han, C.N. Landen, J.G. Trevino, J. Halder, Y.G. Lin, and A.A. Kamat Antiangiogenic and antitumor effects of SRC inhibition in ovarian cancer Cancer Res 66 2006 8633 8639
11. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
12. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
13. A.K. Sood, J.E. Coffin, G.B. Schneider, M.S. Fletcher, B.R. DeYoung, and L.M. Gruman Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion Am J Pathol 165 2004 1087 1095
14. R.O. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673 687
15. M. Guarino Src signaling in cancer invasion J Cell Physiol 223 2010 14 26
16. B. Boyer, Y. Bourgeois, and M.F. Poupon Src kinase contributes to the metastatic spread of carcinoma cells Oncogene 21 2002 2347 2356
17. S. Miotti, A. Tomassetti, I. Facetti, E. Sanna, V. Berno, and S. Canevari Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of Src-related kinases Am J Pathol 167 2005 1411 1427
18. B. Davidson, J.M. Nesland, I. Goldberg, J. Kopolovic, W.H. Gotlieb, and M. Bryne Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study Gynecol Oncol 81 2001 166 171
19. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
20. L.J. Lombardo, F.Y. Lee, P. Chen, D. Norris, J.C. Barrish, and K. Behnia Discovery of N-(2-Chloro-6-methyl-phenyl-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src-Abl kinase inhibitor with potent antitumor activity in preclinical assays J Med Chem 47 2004 6658 6661
21. J. Araujo, and C. Logothetis Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors Cancer Treat Rev 36 2010 492 500
22. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer. National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
23. F.R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, and K. Fager Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure Clin Cancer Res 12 2006 7180 7186
24. F.R. Luo, Y.C. Barrett, Z. Yang, A. Camuso, K. McGlinchey, and M.L. Wen Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor Cancer Chemother Pharmacol 62 2008 1065 1074
25. Sill MW, Yothers GA. A method for utilizing bivariate efficacy outcome measures to screen agents for activity in the 2-stage phase II clinical trials. Technical Report 06-08, Department of Biostatistics, University of Buffalo. Website: http://sphhp.buffalo.edu/biostat/research/techreports/index.php, 2008
26. H.K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, and R. Sayer An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J Clin Oncol 25 2007 517 525
27. A.H. Bild, G. Yao, J.T. Chang, Q. Wang, A. Potti, and D. Chasse Oncogenic pathway signatures in human cancers as a guide to targeted therapies Nature 439 2006 353 357
28. G.E. Konecny, R. Glas, J. Dering, K. Manivong, J. Qi, and R.S. Finn Activity of the multikinase inhibitor dasatinib against ovarian cancer cells Br J Cancer 101 2009 1699 1708
29. D. Teoh, T.A. Yeni, J.M. Tubatt, D.J. Adams, L. Grace, and M.D. Starr Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells Gynecol Oncol 121 2011 187 192
30. E.Y. Yu, G. Wilding, E. Posadas, M. Gross, S. Culine, and C. Massard Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7421 7428
31. L.N. Puls, M. Eadens, and W. Messersmith Current status of Src inhibitors in solid tumors Oncologist 16 2011 566 578
32. H.S. Kim, H.D. Han, G.N. Armaiz-Pena, R.L. Stone, E.J. Nam, and J.W. Lee Functional roles of Src and Fgr in ovarian carcinoma Clin Cancer Res 17 2011 1713 1721
33. B. Sen, S. Peng, D.M. Woods, I. Wistuba, D. Bell, and A.K. El-Naggar STAT-5A-mediated SOCS2 expression regulates JAK2 and STAT3 activity following c-SRC inhibition in head and neck squamous carcinoma Clin Cancer Res 18 2012 127 139
34. L. Strauss, O. Sy, J. Fairchild, C. Fu, A. Rybicki, and S. Yoganathan Biomarker analysis in phase 2 single-agent trials of dasatinib for breast cancer 2009 SABCS #2034